Genetic Polymorphism of Drug Metabolizing Enzymes: New Mutations in CYP2D6 and CYP2A6 Genes in Japanese |
| |
| Authors: | Yokoi Tsuyoshi Kamataki Tetsuya |
| |
| Affiliation: | (1) Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, 920, Japan;(2) Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060, Japan |
| |
| Abstract: | Genetic polymorphism of drug metabolizing enzymes, particularly cytochrome P450 (CYP), is an important cause of adverse drug reactions. Multiple gene mutations in CYP have been shown to be phenotype. The occurrence of genetic polymorphism has been seen in genes for CYP1A1, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A5. This review discusses the molecular mechanism of two genetic polymorphisms, debrisoquine/sparteine (CYP2D6) coumarin (CYP2A6) polymorphisms. In addition, elucidation of gene mutations of CYP2D6 and CYP2A6 in Japanese will be discussed. |
| |
| Keywords: | genetic polymorphism phenotype drug metabolism genotype cytochrome P450 pharmacogenetics clinical pharmacology |
| 本文献已被 SpringerLink 等数据库收录！ |
|
